INTRODUCTION
============

Adequate bowel preparation is essential for effective colonoscopies \[[@b1-kjim-2017-275]-[@b5-kjim-2017-275]\]. Poor bowel preparation results in missed polyps, increased risk of procedural adverse events, and the necessity for repeated examinations \[[@b2-kjim-2017-275],[@b5-kjim-2017-275]\]. An ideal bowel cleansing agent should rapidly empty the fecal material without causing mucosal alteration of the colon or causing electrolyte imbalance. In addition, it should be tolerable and easy to consume \[[@b1-kjim-2017-275],[@b2-kjim-2017-275],[@b4-kjim-2017-275]\]. No available agent satisfies all these characteristics.

High-volume (4-L) polyethylene glycol (PEG) has been widely used for bowel preparation because of its cleaning efficacy and safety \[[@b6-kjim-2017-275]\]. However, some patients do not fully consume the preparation because of the large volume and poor palatability \[[@b1-kjim-2017-275]\]. Low-volume bowel preparations seek to improve patient tolerability. Two-liter PEG with additional ascorbic acid as a laxative (AA + PEG) has similar efficacy compared to 4-L PEG \[[@b7-kjim-2017-275],[@b8-kjim-2017-275]\]. AA + PEG is safe for most patients except for those who are deficient in glucose-6-phosphate dehydrogenase \[[@b8-kjim-2017-275],[@b9-kjim-2017-275]\].

In 2009, a new osmotic preparation termed oral sulfate solution (OSS) was developed for bowel cleansing \[[@b10-kjim-2017-275]\]. This hyperosmolar preparation does not cause significant fluid or electrolyte shifts possibly because sulfate is a poorly absorbed anion. The preparation regimen involves consumption of a reduced volume (946 mL) of the preparation solution and 1,892 mL of water with additional fluid consumption permissible \[[@b1-kjim-2017-275],[@b11-kjim-2017-275]\].

Recent studies have demonstrated the efficacy of OSS compared to conventional bowel cleansing agents and shown comparable or better efficacy with an acceptable safety profile \[[@b10-kjim-2017-275]-[@b15-kjim-2017-275]\]. Three of these studies have compared the efficacy of OSS with AA + PEG using a non-inferiority design. However, their study subjects were Americans \[[@b11-kjim-2017-275],[@b12-kjim-2017-275],[@b14-kjim-2017-275]\]. Such data for Asians are lacking.

Thus, the objective of this randomized, prospective, investigator-blind, parallel study was to compare the efficacy and tolerability of OSS to AA + PEG in Asian patients. Both preparations were in low-volume and given as split doses according to the Korea and United States Food and Drug Administration approved regimens. Outcomes included effectiveness in bowel cleansing, tolerability, and compliance with the preparation.

METHODS
=======

Overview
--------

This was a prospective, randomized, parallel, investigator-blind study of adult patients undergoing elective colonoscopy. Subjects were enrolled from February 1st, 2016 to July 27th, 2016 at two university hospitals in Korea. Both study centers used the same investigational protocols. Subjects received OSS or AA + PEG bowel preparation. A 1:1 ratio with an almost equal distribution of patients was used in each study center. Colonoscopists were unaware of bowel preparation agent used for the patient to ensure that treatment blinding was maintained.

Subjects were patients aged 20 to 70 years who were undergoing screening colonoscopy. Subjects were excluded if they met any of the following criteria: (1) active colitis, suspicion of bowel obstruction or bleeding, (2) severe constipation, (3) ascites, (4) inflammatory bowel disease, (5) previous bowel surgery, (6) heart failure or ischemic heart disease within 6 months prior to enrollment, (7) renal insufficiency, (8) pregnant or breastfeeding, or (9) diagnosis of hypersensitivity. The consent form was approved by the Institutional Review Board of each study center (IRB No. DUIH2015-130, KUGH15296). Written informed consent was obtained from each participating patient.

Administration of study agents
------------------------------

After assignment of bowel preparation agents, subjects consumed a low-residue diet until three days before the colonoscopy. Before the diet, they received information regarding unacceptable foods, including vegetables or grains containing high dietary fiber, fruits containing seeds, seaweed, dry beans, and nuts. All subjects were instructed to fast from the evening before the day of the procedure.

OSS (Innofree, MH Healthcare, Seoul, Korea) contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Contents of each bottle were diluted with water to 473 mL. Each subject was prescribed two bottles of OSS for bowel preparation. One bottle of OSS solution was diluted with water (946 mL) and consumed the evening before the day of the colonoscopy. The second bottle of diluted OSS was consumed the morning of the colonoscopy at least 3 hours prior to the procedure.

AA+PEG (Coolprep, Taejoon Pharm Co., Seoul, Korea) contained (per L) 100 g PEG, 1 g potassium chloride, 2.69 g sodium chloride, 7.5 g sodium sulfate, 4.7 g ascorbic acid, and 5.9 g sodium ascorbate. Subjects who were assigned with AA + PEG were instructed to ingest 1 L of AA + PEG solution and a further 500 mL water in the evening before the day of the procedure. Then they began to consume the remaining 1 L of AA + PEG solution with water 5 hours prior to the procedure. The consumption should be completed at least 3 hours before the colonoscopy. All patients were instructed to return any remaining bowel preparation.

Assessments of bowel preparation quality
----------------------------------------

All study procedures were performed by expert colonoscopists who were blinded to bowel preparation agent. They evaluated the efficacy of bowel cleansing using the Ottawa Bowel Preparation Scale (OBPS) and Boston Bowel Preparation Scale (BBPS) \[[@b16-kjim-2017-275],[@b17-kjim-2017-275]\]. OBPS assesses cleanliness and fluid volume separately. Cleanliness was assessed for the right colon (cecum, ascending), middle colon (transverse, descending), and the rectosigmoid colon. Each colon section was individually rated from 0 to 4 (0, no liquid; 1, minimal liquid with no suctioning required; 2, suction required to view mucosa; 3, wash and suction; 4, solid stool, not washable). Fluid quantity was rated from 0 to 2 for the entire colon (0, minimal; 1, moderate; 2, large). OBPS ranged from 0 (perfect) to 14 (solid stool in each colon segment and copious fluid; i.e., a completely unprepared colon) \[[@b17-kjim-2017-275]\]. Adequate bowel preparation was defined as all scores of each section ≤ 3 and fluid quantity \< 2 \[[@b18-kjim-2017-275]\].

BBPS assessed cleanliness for the right colon (cecum, ascending), transverse colon (transverse, hepatic, and splenic flexure), and the left colon (descending, rectosigmoid colon). Each colon section was individually rated from 0 to 3 (0, unprepared colon segment with mucosa not observed due to solid stool that cannot be cleared; 1, portion of mucosa of the colon segment observed but other areas of the colon segment not well observed due to staining, with residual stool and/or opaque liquid; 2, minor amount of residual staining, small fragments of stool and/or opaque liquid but mucosa of colon segment well observed; 3, entire mucosa of colon segment well observed with no residual staining, small fragments of stool, or opaque liquid). BBPS ranged from 0 (completely unprepared colon) to 9 (perfect). Adequate bowel preparation was defined as all scores of each section ≥ 2 \[[@b16-kjim-2017-275]\].

Investigators participating in this study were instructed on how to assess the bowel preparation scale. A complete colonoscopy was successful cecal intubation by visualization of the ileocecal valve and appendiceal orifice.

Assessments of tolerability and adverse events
----------------------------------------------

After completing the assigned preparation and before the colonoscopy, all subjects completed a questionnaire on compliance (complete intake rate), overall tolerability, taste, abdominal cramping, stomach bloating, nausea, sleep disturbance, and intention to re-intake the same agent. Patients used a 5-point scale for each system (1, none; 2, mild; 3, bothersome; 4, distressing; and 5, severely distressing). This symptom scoring system has been used in previous studies \[[@b12-kjim-2017-275],[@b14-kjim-2017-275]\]. If serious adverse events occurred, physicians assessed symptoms and signs. Additional evaluations were done.

Sample size and statistical analyses
------------------------------------

A hypothesis of no difference between the two treatments in the overall quality of bowel cleansing was postulated. A non-inferiority design was applied. Non-inferiority was defined if the lower limit of the one-sided 97.5 % confidence interval for the difference in success rates between the two treatment groups was \< 15%. At least 80 patients were required for each treatment group to detect a difference in treatment success with 5% type-I error rate and 80% power for a two-tailed chisquare test. Our sample size was based on results from previous studies with PEG solution \[[@b1-kjim-2017-275],[@b2-kjim-2017-275]\]. Based on these data, we decided to enroll at least 90 patients per treatment group for this study. SPSS version 23 (IBM Co., Armonk, NY, USA) was used for all data analyses. Continuous variables were compared by the two-sided t test while categorical variables were compared by Pearson's chi-square test or Fisher's exact test. A *p* value \< 0.05 was considered statistically significant.

RESULTS
=======

Demographics
------------

Initially, 187 subjects were randomized to either of the two bowel preparation regimens. Fourteen subjects were excluded, including one who met the exclusion criteria and 13 who withdrew consent before colonoscopy. Finally, 173 subjects were enrolled, including 86 subjects who received OSS and 87 subjects who received AA + PEG. Demographics and colonoscopy results of these two groups are presented in [Table 1](#t1-kjim-2017-275){ref-type="table"}. Cecal intubation rate was 100% in both groups. Both groups were similar in gender, age, body mass index, smoking history, diet restriction, interval between the last ingestion and the colonoscopy, and cecal intubation time. The average age of study participants was 54.9 ± 10.8 years (range, 25 to 76). Diet restriction was undertaken in 76.7% (66/86) of the OSS group and 86.2% (75/87) of the AA + PEG patients (*p* = 0.12). Mean interval time between the end of the last purgative ingestion and the start of colonoscopy was 3.26 ± 0.27 hours for the OSS group and 3.34 ± 0.32 hours for the AA + PEG group. Overall mean cecal intubation time was 243 ± 143 seconds without showing significant group difference (240 ± 122 seconds for OSS vs. 246 ± 161 seconds for AA + PEG, *p* = 0.78).

Efficacy of bowel cleansing
---------------------------

[Table 2](#t2-kjim-2017-275){ref-type="table"} presents OBPS cleansing scores for the two groups. The rate of adequate bowel preparation was 93.0% in the OSS group and 77.0% in the AA + PEG group (*p* = 0.005). Total OBPS score was 2.80 ± 2.48 in the OSS group, which was significantly (*p* \< 0.001) lower (i.e., better) than (4.49 ± 3.08) of the AA + PEG group. Scores for the right, middle, and rectosigmoid colon segments were also significantly lower in the OSS group than THOSE in the AA + PEG group. However, quantities of fluids were comparable between the two groups (0.64 ± 0.51 in the OSS group vs. 0.76 ± 0.55 in the AA + PEG group, *p* = 0.14). Results of comparison of bowel preparations based on BBPS are presented in [Table 3](#t3-kjim-2017-275){ref-type="table"}. The rate of adequate bowel preparation was not significantly different between OSS and AA + PEG groups (86.0% vs. 73.6%, *p* = 0.06). However, total BBPS score was significantly higher (i.e., better) in the OSS group (7.43 ± 1.49 vs. 6.51 ± 1.76, *p* \< 0.001). Scores for the right, transverse, and left colon sections were consistently and significantly higher in the OSS group than those in the AA + PEG group.

Compliance, safety, and tolerability
------------------------------------

Data collected from the patient questionnaire about the compliance and tolerability of the bowel preparation are presented in [Table 4](#t4-kjim-2017-275){ref-type="table"}. Among a total of 173 subjects, 164 subjects (94.7%) ingested the full dosage regimen. Nine subjects (5.2%) ingested more than half the dose regimen, but not the full dosage. There was no significant difference in overall satisfaction between OSS and AA + PEG groups (2.01 ± 1.09 vs. 1.98 ± 0.98, *p* = 0.826).

No serious adverse effects developed after ingestion of either preparation regimen. The OSS group had significantly higher (i.e., worse) scores for nausea (1.92 ± 0.94 vs. 1.54 ± 0.76, *p* = 0.004) and abdominal cramping (1.45 ± 0.78 vs. 1.17 ± 0.51, *p* = 0.006). However, average scores for both groups were \< 2 (mild). Significant differences for taste, stomach bloating, and sleep disturbance between the two groups were not evident. Intention to re-intake the same preparation for future colonoscopies was similar in both groups.

DISCUSSION
==========

We described a prospective, randomized, parallel, investigator-blind trial that compared the efficacy, safety, and tolerability between OSS and AA + PEG bowel preparations. This is the first report to analyze the efficacy and acceptability of OSS formulation in Korean subjects. Clinical outcomes were collected from 173 patients at university hospitals in Korea during screening colonoscopies. We demonstrated that OSS was superior to AA + PEG for colon cleansing. Tolerability and adverse events associated with these two preparations were similar except for nausea and abdominal cramping. However, these adverse events were generally acceptable.

A previous study has shown that OSS provides superior segmental cleansing compared to 4 L PEG \[[@b13-kjim-2017-275]\]. However, OSS was not directly compared to 4 L split-dose PEG \[[@b13-kjim-2017-275]\]. Cleansing efficacies were worse if subjects received full AA + PEG dose in the evening before the procedure compared to split-dose \[[@b7-kjim-2017-275]\]. In this study, splitdose regimens of OSS and AA + PEG were implemented to provide more successful preparation efficacy and less gastrointestinal adverse events compared to the sameday regimen \[[@b11-kjim-2017-275]\].

Previous studies have frequently used OBPS and BBPS bowel cleansing scoring systems \[[@b16-kjim-2017-275],[@b17-kjim-2017-275]\]. The BBPS is a valid and reliable measure of bowel preparation that aggregates scores of three broad segments of the colon rated during withdrawal of the colonoscope after washing and suctioning of the fluid. Consequently, this scoring system does not include the quantity of fluid in the colon which requires various other scores \[[@b16-kjim-2017-275]\]. The OBPS rates three colonic segments independently. Their scores are then summed at the end of the colonoscopic examination to give a total score. Furthermore, the OBPS includes an overall fluid quantity in the colon (rated 0 to 2) which allows subjective estimation of residual liquid. Thus, OBPS is a simple, objectively framed bowel preparation quality scale that assesses colonic segments individually and overall colonic fluid. It provides a summary score for the entire colon. This scale has high inter-observer reliability for total scoring and segmental colonic preparation quality \[[@b17-kjim-2017-275]\]. The strength of our study was that we used two overall grading scales which included segmental scoring to validate the quality of the bowel preparation. Segmental scoring was conducted separately. Results supported the overall efficacy. Scores for the three colon sections were significantly higher in the OSS group than those in the AA + PEG group.

Adenoma detection rate is defined as the percentage of procedures per colonoscopist in which at least one adenoma is detected. It has been considered as a strong quality indicator for effective colonoscopy \[[@b19-kjim-2017-275]-[@b22-kjim-2017-275]\]. However, most patients enrolled in the present study had experience of colonoscopic examination or a prior history of colon polyp. We could not analyze polyp detection rate or adenoma detection rate for this reason. There was no difference between the two study groups regarding serious adverse events except for nausea and abdominal cramping which did not require further medical management. In the symptom questionnaire, the OSS group scored significantly higher for nausea and abdominal cramping compared to the AA + PEG group. Differences in taste among Asian subjects may cause higher scores for nausea than other Caucasian studies \[[@b11-kjim-2017-275],[@b13-kjim-2017-275],[@b14-kjim-2017-275]\]. However, the degree of adverse symptoms in both groups was less than mild. There were no significant differences between the two groups for taste, stomach bloating, or sleep disturbance. These problems were also acceptable.

Our study has several limitations. First, we used a cleansing score that assessed three bowel segments. Recent studies have shown a more detailed evaluation that divides the colon into five or six segments \[[@b7-kjim-2017-275],[@b23-kjim-2017-275]\]. However, both BBPS and OBPS scores have been extensively validated for general use in clinical studies \[[@b16-kjim-2017-275]\]. Second, inter-investigator variation for bowel preparation scores unfortunately occurred in this investigation. Colonoscopists in two hospitals had no opportunity to reach a sufficient agreement about measurement of two bowel preparation scales. Third, AA + PEG bowel preparation adequacy scored less than that reported by other studies (88% to 90%) \[[@b7-kjim-2017-275],[@b24-kjim-2017-275]\]. The small number of subjects enrolled in our study might have led to this discrepancy.

In summary, OSS provided a non-inferior efficacious bowel cleansing than AA + PEG regimen without compromising safety or tolerability. Bowel cleansing quality and patients' acceptance of the OSS formulation in Asian people indicate the potential of OSS as an alternative bowel cleansing method to AA + PEG for clinical use. Further prospective studies in larger populations are needed to confirm this finding.

KEY MESSAGE
===========

1\. Oral sulfate solution (OSS) is an emerging cleansing agent for bowel preparation in the world.

2\. OSS is also an excellent efficacious bowel cleansing agent in Asian people.

3\. Patients' acceptance was generally good in Asian people, although patients receiving OSS had more nausea and abdominal cramping than those receiving ascorbic acid plus polyethylene glycol.
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###### 

Demographic, clinical, and endoscopic characteristics of subjects

  Characteristic                                                OSS (n = 86)    AA + PEG (n = 87)   *p* value
  ------------------------------------------------------------- --------------- ------------------- -----------
  Age, yr                                                       53.57 ± 10.99   56.22 ± 10.54       0.11
  Male sex                                                      37 (43.0)       39 (44.8)           0.88
  Body mass index, kg/m^2^                                      23.70 ± 3.00    23.90 ± 3.77        0.71
  Current smoking                                               18 (20.9)       19 (21.8)           1.00
  Diabetes                                                      8 (10.1)        8 (9.2)             1.00
  Hypertension                                                  20 (23.3)       23 (26.4)           0.73
  Previous colonoscopy                                          62 (74.4)       63 (72.4)           0.86
  Diet restriction                                              66 (76.7)       75 (86.2)           0.12
  Interval between the last ingestion and the colonoscopy, hr   3.26 ± 0.27     3.34 ± 0.32         0.10
  Cecal intubation time, sec                                    240 ± 122       246 ± 161           0.78

Values are presented as mean ± SD or number (%).

OSS, oral sulfate solution; AA + PEG, ascorbic acid plus polyethylene glycol.

###### 

Outcome of bowel cleansing according to Ottawa Bowel Preparation Scale

  Variable                     OSS (n = 86)   AA + PEG (n = 87)   *p* value
  ---------------------------- -------------- ------------------- -----------
  Total score                  2.80 ± 2.48    4.49 ± 3.08         \< 0.001
   Right colon                 0.73 ± 0.95    1.37 ± 1.15         \< 0.001
   Middle colon                0.69 ± 0.94    1.24 ± 1.08         \< 0.001
   Rectosigmoid colon          0.83 ± 0.96    1.30 ± 1.06         0.002
  Quantity of fluid            0.64 ± 0.51    0.76 ± 0.55         0.140
  Adequate bowel preparation   80 (93.0)      67 (77.0)           0.005

Values are presented as mean ± SD or number (%). Adequate bowel preparation was defined as all scores of each section ≤ 2 and fluid quantity ≤ 1.

OSS, oral sulfate solution; AA + PEG, ascorbic acid plus polyethylene glycol.

###### 

Outcome of bowel cleansing according to Boston Bowel Preparation Scale

  Variable                     OSS (n = 86)   AA + PEG (n = 87)   *p* value
  ---------------------------- -------------- ------------------- -----------
  Total score                  7.43 ± 1.49    6.51 ± 1.76         \< 0.001
   Right colon                 2.36 ± 0.68    2.08 ± 0.71         0.009
   Transverse colon            2.52 ± 0.59    2.23 ± 0.74         0.005
   Left colon                  2.55 ± 0.59    2.21 ± 0.73         0.001
  Adequate bowel preparation   74 (86.0)      64 (73.6)           0.060

Values are presented as mean ± SD or number (%). Adequate bowel preparation was defined as all scores of each section ≥ 2.

OSS, oral sulfate solution: AA + PEG, ascorbic acid plus polyethylene glycol.

###### 

Compliance and adverse effects of bowel preparation regimen

  Variable                                                              OSS (n = 86)   AA + PEG (n = 87)   *p* value
  --------------------------------------------------------------------- -------------- ------------------- -----------
  Complete intake rate                                                  82 (95.3)      82 (94.3)           1.000
  Overall satisfaction^[a](#tfn1-kjim-2017-275){ref-type="table-fn"}^   2.01 ± 1.09    1.98 ± 0.98         0.826
  Intention to re-intake                                                69 (80.2)      72 (82.8)           0.699
  Taste^[a](#tfn1-kjim-2017-275){ref-type="table-fn"}^                  1.98 ± 1.07    1.83 ± 0.93         0.330
  Nausea^[a](#tfn1-kjim-2017-275){ref-type="table-fn"}^                 1.92 ± 0.94    1.54 ± 0.76         0.004
  Stomach bloating^[a](#tfn1-kjim-2017-275){ref-type="table-fn"}^       1.98 ± 1.04    1.76 ± 0.88         0.137
  Abdominal cramping^[a](#tfn1-kjim-2017-275){ref-type="table-fn"}^     1.45 ± 0.78    1.17 ± 0.51         0.006
  Sleep disturbance^[a](#tfn1-kjim-2017-275){ref-type="table-fn"}^      1.28 ± 0.73    1.21 ± 0.57         0.471

Values are presented as number (%) or mean ± SD.

OSS, oral sulfate solution: AA + PEG, ascorbic acid plus polyethylene glycol.

Ratings, 1 = none; to 5 = severely distressing.
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